NK cell receptor engineering: A New Hope for cancer immunotherapy
| dc.rights.license | CC-BY-NC-ND | |
| dc.contributor.advisor | Caiazzo, Massimiliano | |
| dc.contributor.author | Papamoschou, Billy | |
| dc.date.accessioned | 2024-07-02T12:31:29Z | |
| dc.date.available | 2024-07-02T12:31:29Z | |
| dc.date.issued | 2024 | |
| dc.identifier.uri | https://studenttheses.uu.nl/handle/20.500.12932/46584 | |
| dc.description.sponsorship | Utrecht University | |
| dc.language.iso | EN | |
| dc.subject | In recent years, Natural killer cells have become a rising alternative for cancer immunotherapeutic purposes. Their exploitation for adoptive cell transfer (ACT) offers a safer and broader application compared to T cell-focused therapies due to significantly less toxicity and a wide variety of autologous and allogeneic NK cell sources. To this direction, this review focuses on the preclinical and current clinical studies regarding the engineering of the activating, inhibitory and chemotactic NK. | |
| dc.title | NK cell receptor engineering: A New Hope for cancer immunotherapy | |
| dc.type.content | Master Thesis | |
| dc.rights.accessrights | Open Access | |
| dc.subject.courseuu | Drug Innovation | |
| dc.thesis.id | 21345 |
